Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 27, 2004
Business Overview: Henry Schein is the largest distributor of healthcare products and services to office-based practitioners in North America and Europe. Operations are divided into two segments: Healthcare Distribution (dental, medical, veterinary, and international) and Technology (practice management software).
Key Financial Metrics
| Metric | Q1 2004 | Q1 2003 |
|---|---|---|
| Net Sales | $886.6 million | $738.0 million |
| Gross Profit | $230.8 million | $201.4 million |
| Gross Margin | 26.0% | 27.3% |
| Operating Income | $46.3 million | $42.2 million |
| Net Income | $28.4 million | $24.8 million |
| Diluted EPS | $0.63 | $0.55 |
| Cash and Equivalents | $73.1 million | $187.0 million (end of period) |
| Working Capital | $606.8 million | $637.3 million (Dec 27, 2003) |
| Long-Term Debt | $273.3 million | $247.1 million (Dec 27, 2003) |
Cash Flow Summary: Net cash used in operating activities was $20.3 million. Net cash used in investing activities was $87.9 million, driven primarily by payments related to pending acquisitions. Net cash provided by financing activities was $25.4 million.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 20.1% year-over-year. The Healthcare Distribution segment grew 20.3%, driven by a 22.5% increase in Medical sales and a 30.8% increase in International sales (partially due to favorable exchange rates).
- Margin Compression: Gross margin decreased to 26.0% from 27.3%. The Healthcare Distribution margin fell to 25.0% due to a higher mix of lower-margin pharmaceutical products. Technology margin decreased to 74.1% due to sales mix changes.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 15.9% but decreased as a percentage of sales to 20.8% from 21.6%, reflecting infrastructure leverage.
- Liquidity: Cash and cash equivalents declined significantly from $157.4 million to $73.1 million, primarily due to $43 million paid toward pending European acquisitions and increased inventory levels.
Guidance, Outlook, and Risks
Acquisitions and Capital Needs: The company is awaiting regulatory approval for the acquisition of demedis GmbH and Euro Dental Holding GmbH (EDH) in Europe. A total purchase price of approximately 255 million euros is expected, with $43 million already paid. The remaining balance is expected to be funded via a $150 million bridge loan and permanent financing. Closing is expected in mid-2004.
Outlook: Management anticipates continued sales growth and increased working capital requirements. Capital expenditures for the remainder of the fiscal year are estimated at $30.0 million for facility modernization and IT infrastructure.
Risks and Contingencies:
- Legal Proceedings: The company is a defendant in approximately 15 product liability cases (mostly latex glove allergies) and a Texas class action regarding practice management software (class certification denied, individual claims remain). Management believes insurance covers these risks.
- Market Risks: Exposure to foreign currency fluctuations, interest rate changes on variable-rate debt, and industry consolidation.
- Seasonality: First-quarter results are typically lower due to customer purchasing patterns in the prior quarter.
Investor Verification Checklist
- Acquisition Closing: Verify the status of regulatory approvals for the demedis and EDH acquisitions and the finalization of the $150 million bridge loan.
- Margin Trends: Monitor the mix of pharmaceutical sales in the Medical segment to assess if gross margin compression is a temporary or structural shift.
- Working Capital: Track accounts receivable days sales outstanding (currently 48.4 days) and inventory turnover (6.6 turns) to ensure liquidity remains sufficient for the pending acquisition closing.
- Legal Exposure: Review updates on the Texas class action and product liability claims to ensure no material uninsured losses emerge.